Tons of great teaching pearls from this phenomenal PET/CT in #lymphoma session. Will start a #thread here. #ASH20 #lymsm
First, staging PET for DLBCL is more sensitive than BMBx for bone marrow involvement. Some do not do BMBx for DLBCL.
1/
First, staging PET for DLBCL is more sensitive than BMBx for bone marrow involvement. Some do not do BMBx for DLBCL.
1/
With regards to interim PET, after C2 best to determine responders, after C4 best to determine non-responders. After C4 non-responder definition = Deauville 5 or change in SUVmax <70%. Caveat: residual SUVmax >5 = non-responder.
2/
2/
When iPET is negative, it is 1) reassuring for patients, 2) supports omission of RT in limited-stage DLBCL, and 3) identifies chemosensitivity accurately.
3/
3/
If end-of-treatment PET is positive, treating with RT results in similar outcomes to those with negative EOT-PET. 33% of EOT-PET+ patients will not progress! PMBCL is a different beast: EOT PET is often positive and does not mean poor prognosis. #lymsm #ASH20
4/
4/
On to follicular lymphoma: EOT-PET is highly predictive of PFS in high tumor burden FL (EOT-PET+ patients have much higher risk of death!). Also interesting: SUVmax >10 was not associated with early HT in GALLIUM study; do we need to rebiopsy this patients? #ASH20 #lymsm
5/5
5/5